Services / Cancer Care / Research / Clinical Trials /

Clinical Trial

« Back to List

MEL 28

Posted by: Fred J. Kudrik, MD, Principal Investigator | Posted Date: December 31, 2012

Status: OPEN - IST
Research Hotline: 803-461-3708

Details: A Phase III, Randomized, Double-Blinded Study Comparing the combination of the BRAF Inhibitor, GSK2118436 and the MEK Inhibitor, GSK1120212 to Each Single Agent Combined with Placebo in Subjects with Advanced (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation-Positive Melanoma.

This clinical trial is being offered at the following location:Lexington Oncology

Bookmark and Share